{"id":"W4316927819","doi":"10.1007/s13555-022-00883-y","title":"Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Dalhousie University","funders":"UCB Pharma; Sun Pharma; Mitsubishi Tanabe Pharma Corporation; Taiho Pharmaceutical; Celgene; Eisai; Sanofi; Amgen; Pfizer; Meiji Seika Pharma; Kyowa Hakko Kirin; LEO Pharma; Torii Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ustekinumab; Plaque psoriasis; Placebo; Medicine; Psoriasis; Dermatology; Internal medicine; Alternative medicine; Pathology; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002363667,0.0002998816,0.0007560062,0.0004006693,0.0001847838,0.00001623347,0.00008479497,0.0002779577,0.00003844541],"category_scores_gemma":[0.00002809777,0.0002190357,0.00002908265,0.0003007818,0.0001917909,0.0001011285,0.00004775163,0.000191816,0.00002521213],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001528205,"about_ca_system_score_gemma":0.00002822671,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00010397,"about_ca_topic_score_gemma":0.0004143523,"domain_scores_codex":[0.9981421,0.0006078209,0.0003621567,0.0004600114,0.00003833619,0.0003895468],"domain_scores_gemma":[0.9990157,0.000638396,0.0000970757,0.0001899418,0.00002245005,0.00003644956],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1121962,0.002966069,0.8151273,0.00002352853,0.001095357,0.00036543,0.01674335,0.000002880236,0.0006288161,0.00007963297,0.00009978691,0.05067172],"study_design_scores_gemma":[0.3979007,0.001293686,0.5965061,0.00003318945,0.0001095787,0.0001704726,0.002116504,0.00001900846,0.0003858252,0.00005512389,0.001070522,0.000339254],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951366,0.00262871,6.349018e-7,0.0003272173,0.0001413258,0.001591685,0.00004722198,0.00005887198,0.00006773364],"genre_scores_gemma":[0.9976501,0.001791355,0.000005723312,0.0001138428,0.0000070546,0.0002253808,0.0001213283,0.00001992941,0.00006531367],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2857046,"threshold_uncertainty_score":0.8932018,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01355195460515869,"score_gpt":0.2571772653719167,"score_spread":0.243625310766758,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}